Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein, J. Christine Ye, Alan Howard, Manisha Bhutani, Nicole Gormley, Theresa Hahn, Jens Hillengass, Amrita Krishnan, C. Ola Landgren, Nikhil C. Munshi, Stefania Oliva, Roger G. Owen, Marcelo C. Pasquini, Noemi Puig, Niels Weinhold, Katja Weisel, Philip L. McCarthy

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

Original languageEnglish (US)
Pages (from-to)e89-e97
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number3
DOIs
StatePublished - Mar 2019

    Fingerprint

Keywords

  • Autologous stem cell transplantation
  • Endpoint
  • Immune profiling
  • Minimal residual disease
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Holstein, S. A., Ye, J. C., Howard, A., Bhutani, M., Gormley, N., Hahn, T., Hillengass, J., Krishnan, A., Landgren, C. O., Munshi, N. C., Oliva, S., Owen, R. G., Pasquini, M. C., Puig, N., Weinhold, N., Weisel, K., & McCarthy, P. L. (2019). Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 25(3), e89-e97. https://doi.org/10.1016/j.bbmt.2018.11.001